1 / 14

The Stop TB Partnership Task Force on “Retooling” Update for the Working Groups Annual Meeting

The Stop TB Partnership Task Force on “Retooling” Update for the Working Groups Annual Meeting. Vinand Nantulya & Nina Schwalbe, co-chairs of Task Force. Pipeline Noted. Rationale for Task force.

angelica-rosales
Download Presentation

The Stop TB Partnership Task Force on “Retooling” Update for the Working Groups Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Stop TB Partnership Task Force on “Retooling”Update for the Working Groups Annual Meeting Vinand Nantulya & Nina Schwalbe, co-chairs of Task Force

  2. Pipeline Noted

  3. Rationale for Task force • As noted by Global Plan in previous slide a steady stream of innovations is coming beginning as early as 2007 • But major challenges lie ahead in adopting these tools • Rapid adoption will require planning and preparedness

  4. Task Force on Retooling Created by the Coordinating Board in Assisi, November 2005 to help prepare the TB community for the adoption, introduction and implementation of new/improved diagnostics, drugs, and vaccines

  5. Terms of Reference (1) • Develop a framework/guideline • Consolidate information from tools working groups (timelines, milestones, etc) • Create dialogue among stakeholders • Facilitate mobilization of resources

  6. Terms of Reference (2) • Consolidate lessons learned from other innovations • Fast track incorporation in WHO and national policy • Enhance communication among working groups • Facilitate introduction of operations research and generate evidence around new tools

  7. Composition of Task Force • Working group members, designated by chairs • Key sub groups (laboratory, GDF, poverty) • National TB Program Managers from high- burden countries • WHO Stop TB Department and other relevant WHO departments • Stop TB Partnership Secretariat (as secretary)

  8. Activities to date • July face to face meeting in Geneva • Agreement to produce framework document • Commissioning of MSH to draft document, under guidance from task force core group (weekly teleconferences) • Completion of draft guide for presentation to Coordinating Board in November 2006

  9. Objectives of the guide • Provide a common framework to discuss the adoption of new tools for TB control; • Identify some key issues that need to be addressed to accelerate the adoption and implementation; and • Provide guidance on what actions are needed for adoption, access and proper use by the community.

  10. Key elements (1):Availability of tools for adoption • For diagnostics availability is after the demonstration studies • For drugs and vaccines it is after Phase III clinical trials

  11. Key elements (2): The document • Identifies key challenges to adoption and implementation of new technologies; • Proposes key principles to facilitate appropriate and timely adoption and implementation; • Provides overview of technical and operational considerations for global and national levels.

  12. Key elements (3): Annexes • Overview of selected new medicines, diagnostics and vaccines in the pipeline; • Listing of key actions for the adoption and implementation of each technology category; • Illustrative generic timeline for adoption, introduction and implementation; • List of key readings that provide more detailed discussions of the issues and road maps.

  13. Next steps • Expansion of task force membership • Additional national TB program managers • Members of WHO essential medicines policy group • Additional members of ACSM, DOTS+ and DOTS expansion working groups • Dissemination of framework document • Development of additional documents and guidelines • Guidance on stakeholder engagement • Updated pipeline chart • Retooling monitoring and evaluation framework • Illustrative timelines for post regulatory process • Recommendations for the introductions of specific new tools

  14. Task Force Members • Rachel Bauquerez (secretariat) • Leopold Blac • Saidi Egwaga • Sara England (secretariat) • Ulrich Joseph Furth (core committee) • Christy Hanson (core committee) • Barbara Laughon • Lindiwe Mvusi • Aziz Mohammed • Vinand Nantulya (co-chair, core committee) • Ikushi Onazaki • Philip Chukwuka Onyebujoh (core committee) • Andrew Ramsey (core committee) • Nina Schwalbe (co-chair, core committee) • Birte Holme Sorensen • Javid Syed (core committee) • Karen Weyer • Patrick Zuber • Carole Francis MSH team: Naranjan Konduri, David Lee, Evan Lee, Helena Walkowiak

More Related